“Restoring Cell Function to Block VEGF”

Integrin peptide therapy Luminate shows potential of extending DME treatment.

Anti-VEGF drugs have proven to be effective treatments for diabetic macular edema, but about half of this population does not respond to anti-VEGF therapy and monthly injections can be burdensome. A readout from the DEL MAR Phase IIB Stage 2 clinical trial of the integrin peptide agent Luminate (Allegro Ophthalmics) as sequential therapy with anti-VEGF shows the potential of extending out those injections.

To read the article, please visit Retina Specialist“Restoring Cell Function to Block VEGF”